CompletedNCT02153502
AVP-786 Added to Antidepressants for Depression That Has Not Improved Enough
About this title
Read the official source — NCT02153502Medication studyAges 18+United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Birmingham and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 1, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 206
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT02153502
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Bellflower · Costa Mesa
26 more locations
- Garden Grove
- Lomita
- Oceanside
- Riverside
- Santa Ana
- Sherman Oaks
- Denver
- Bradenton
- Jacksonville
- Miami
- Orange City
- Orlando
- Decatur
- Hoffman Estates
- Valparaiso
- Baltimore
- Glen Burnie
- Boston
- Brooklyn
- New York
- Staten Island
- Garfield Heights
- Oklahoma City
- Tulsa
- Philadelphia
- Murray
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) and Placebo.
Who was this study for?
Listed age limits: from 18 years.
